Next Gen Cardiovascular Treatments Market Size, Report by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Next-Gen Cardiovascular Treatments Market

5.1. COVID-19 Landscape: Next-Gen Cardiovascular Treatments Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Next-Gen Cardiovascular Treatments Market, By Treatment Type

8.1. Next-Gen Cardiovascular Treatments Market Revenue and Volume, by Treatment Type

8.1.1. Pharmacological Therapies

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Interventional Devices

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Regenerative/Cell Therapy

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Next-Gen Cardiovascular Treatments Market, By Disease Indication

9.1. Next-Gen Cardiovascular Treatments Market Revenue and Volume, by Disease Indication

9.1.1. Atherosclerosis/Coronary Artery Disease (CAD)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Heart Failure

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Arrhythmias

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Hypertension

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Peripheral Artery Disease (PAD)

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Valvular Diseases (e.g., TAVR-related interventions)

9.1.6.1. Market Revenue and Volume Forecast

Chapter 10. Global Next-Gen Cardiovascular Treatments Market, By Modality

10.1. Drug-Based-Gen Cardiovascular Treatments Market Revenue and Volume, by Modality

10.1.1. Drug-Based

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Device-Based (Implants, Delivery Systems)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Biologic/Cell-Based Therapies

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Next-Gen Cardiovascular Treatments Market, By End-User

11.1. Next-Gen Cardiovascular Treatments Market Revenue and Volume, by End-User

11.1.1. Hospitals & Cardiac Centers

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Ambulatory Surgical Centers

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Specialty Clinics

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Research Institutes

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Next-Gen Cardiovascular Treatments Market, By Distribution Channel

12.1. Next-Gen Cardiovascular Treatments Market Revenue and Volume, by Distribution Channel

12.1.1. Institutional Sales (Hospitals & Systems)

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Direct-to-Physician/Clinic

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Online & Specialty Pharmacies

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. Global Next-Gen Cardiovascular Treatments Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.3. Market Revenue and Volume Forecast, by Modality

13.1.4. Market Revenue and Volume Forecast, by End-User

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.6.3. Market Revenue and Volume Forecast, by Modality

13.1.6.4. Market Revenue and Volume Forecast, by End-User

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.7.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.7.3. Market Revenue and Volume Forecast, by Modality

13.1.7.4. Market Revenue and Volume Forecast, by End-User

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.3. Market Revenue and Volume Forecast, by Modality

13.2.4. Market Revenue and Volume Forecast, by End-User

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.6.3. Market Revenue and Volume Forecast, by Modality

13.2.7. Market Revenue and Volume Forecast, by End-User

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.9.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.9.3. Market Revenue and Volume Forecast, by Modality

13.2.10. Market Revenue and Volume Forecast, by End-User

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.12.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.12.3. Market Revenue and Volume Forecast, by Modality

13.2.12.4. Market Revenue and Volume Forecast, by End-User

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.14.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.14.3. Market Revenue and Volume Forecast, by Modality

13.2.14.4. Market Revenue and Volume Forecast, by End-User

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.3. Market Revenue and Volume Forecast, by Modality

13.3.4. Market Revenue and Volume Forecast, by End-User

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.6.3. Market Revenue and Volume Forecast, by Modality

13.3.6.4. Market Revenue and Volume Forecast, by End-User

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.8.3. Market Revenue and Volume Forecast, by Modality

13.3.8.4. Market Revenue and Volume Forecast, by End-User

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.10.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.10.3. Market Revenue and Volume Forecast, by Modality

13.3.10.4. Market Revenue and Volume Forecast, by End-User

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.11.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.11.3. Market Revenue and Volume Forecast, by Modality

13.3.11.4. Market Revenue and Volume Forecast, by End-User

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.3. Market Revenue and Volume Forecast, by Modality

13.4.4. Market Revenue and Volume Forecast, by End-User

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.6.3. Market Revenue and Volume Forecast, by Modality

13.4.6.4. Market Revenue and Volume Forecast, by End-User

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.8.3. Market Revenue and Volume Forecast, by Modality

13.4.8.4. Market Revenue and Volume Forecast, by End-User

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.10.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.10.3. Market Revenue and Volume Forecast, by Modality

13.4.10.4. Market Revenue and Volume Forecast, by End-User

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.11.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.11.3. Market Revenue and Volume Forecast, by Modality

13.4.11.4. Market Revenue and Volume Forecast, by End-User

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.3. Market Revenue and Volume Forecast, by Modality

13.5.4. Market Revenue and Volume Forecast, by End-User

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.6.3. Market Revenue and Volume Forecast, by Modality

13.5.6.4. Market Revenue and Volume Forecast, by End-User

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.8.3. Market Revenue and Volume Forecast, by Modality

13.5.8.4. Market Revenue and Volume Forecast, by End-User

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 14. Company Profiles

14.1. Amgen Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. AstraZeneca

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Ionis Pharmaceuticals

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Bristol-Myers Squibb (BMS)

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Bayer AG

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Pfizer Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Abbott Laboratories

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Medtronic plc

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Biotronik SE & Co. KG

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. OrbusNeich Medical

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The major players in the next-gen cardiovascular treatments market include Novartis AG, Amgen Inc., Alnylam Pharmaceuticals, AstraZeneca, Moderna, Inc., Ionis Pharmaceuticals, Bristol-Myers Squibb (BMS), Bayer AG, Pfizer Inc., BioCardia Inc., Abbott Laboratories, Medtronic plc, Edwards Lifesciences, Biotronik SE & Co. KG, Shockwave Medical, Inc., OrbusNeich Medical, Recardio Inc., Regenxbio Inc., Verve Therapeutics, and CRISPR Therapeutics.

The driving factors of the next-gen cardiovascular treatments market are the increasing prevalence of CVDs, technological progress, and a shift toward minimally invasive procedures.

North America region will lead the global next-gen cardiovascular treatments market during the forecast period 2025 to 2034.